Chemical Facility Safety Working Group Issues 90-Day Progress Report
Client Alert | 1 min read | 12.24.13
On December 20, 2013, a multiagency working group issued a report on its progress toward improving safety and security at U.S. chemical facilities. Prompted by the April 2013 ammonium-nitrate explosion in West, Texas, President Obama issued Executive Order 13650, which established the Chemical Facility Safety and Security Working Group. The Group includes, among others, the Occupational Safety and Health Administration (OSHA), the Department of Homeland Security (DHS), and the Environmental Protection Agency. Its progress report touts the "important steps" it has taken in the three-and-a-half months since EO 13650. These steps include public listening sessions to gather stakeholder input and a pilot program in New York and New Jersey to test interagency collaboration as well as federal coordination with state, local, and tribal partners. Such future coordination may include DHS's sharing Chemical Facility Anti-Terrorism Standards (CFATS) data with state, local, and tribal emergency-planning committees.
The four-page report also describes the Working Group's desire "to harmonize the collection and exchange of information to streamline enforcement processes, inform decision-makers at all levels of government and first responders, and avoid duplication of regulatory requirements." Although accomplishing these goals might ease regulated entities' information-sharing burden, increased interagency cooperation may also enhance the government's enforcement capabilities under existing regulations. It is thus critical that stakeholders involved in chemical production, chemical storage, and agricultural supply activities stay current on the Working Group's progress. Those in the oil and gas sector, in particular, should take note of OSHA's recent "request for information" relating to its Process Safety Management (PSM) standard.
Stakeholders may learn more about the Working Group and its efforts by visiting its website. The Group has scheduled four listening sessions in January at which stakeholders may comment on the Group's work. Stakeholders may also submit written comments by email to eo.chemical@hq.dhs.gov.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
